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Introduction and objectives
The gold standard treatment for muscle invasive bladder cancer is open radical cystectomy (ORC) with pelvic lymph node dissection and 
urinary diversion. Robot-assisted radical cystectomy (RARC) is still considered not a standard of care because of concerns about
perioperative patient safety and long-term functional and oncological outcomes and the added direct cost of robotic surgery.
We assessed the perioperative results and complication rates of both procedures in a single academic center.
Methods
Clinical data of the first 67 patients undergoing RARC between May 2013 and 
Total (n=117) Open (n=50) RARC (n=67) p-value
Patient and tumor characteristics
Male [n (%)] 95 (81.2) 40 (80.0) 55 (82.1) 0.775
Age [mean (95%CI)] 69 (67 – 71) 71 (68 – 74) 68 (65 – 70) 0.068
October 2015 were prospectively documented (EC 2013/874) and retrospectively 
compared with the last 50 patients undergoing ORC between November 2010 and 
May 2013 in a single academic center.
ORC was performed by a senior surgeon or a supervised junior surgeon (KD), 
BMI [median (range)] 26 (17 – 38) 25 (18 – 38) 26 (17 – 36) 0.232
ASA [n (%)] I 1 (0.8) 1 (2.0) 0 (0.0) 0.045
II 53 (45.3) 17 (34.0) 36 (53.7)
III 58 (49.6) 28 (56.0) 30 (44.8)
IV 5 (4.3) 4 (8.0) 1 (1.5)
Neoadj. chemo [n (%)] 19 (16.6) 3 (6.0) 16 (23.9) 0.009
preop BCG [n (%)] 32 (27.4) 14 (28.0) 18 (26.9) 0.892
whereas RARC was done by a single surgeon (KD) after training by an experienced 
RARC surgeon (AH). Urinary diversion was predominantly performed intracorporeal
(88%). Complications were graded on day 30 and 90 using the Clavien Dindo
classification. SPSS v23 was used for statistical analysis.
pT stage [n (%)] pT0 6 (5.2) 2 (4.2) 4 (6.0) 0.530
≤ pT1 40 (34.8) 16 (33.3) 24 (35.8)
pT2 14 (12.2) 4 (8.3) 10 (14.9)
pT3 34 (29.6) 14 (29.2) 20 (29.9)
pT4 2 (18.3) 12 (25.0) 9 (13.4)
Prostate Ca [n (%)] 31 (32.6) 13 (32.5) 18 (32.7) 0.981
Operative parameters
Results
Both groups are fairly comparable regarding patient and tumor characteristics.
PLND [n (%)] 102 (87.2) 37 (74.0) 65 (97.0) <0.001
pN+ [n (%)] 39 (33.3) 15 (30.0) 24 (35.8) 0.509
N yield [median (range)] 14 (0 – 37) 4 (0 – 37) 17 (0 – 32) <0.001
Positive margin bladder [n (%)] 14 (12.5) 12 (26.1) 2 (3.0) <0.001
5 missing 4 missing 1 missing
Diversion method
[n (%)]
ileal conduit 63 (53.8) 26 (52.0) 37 (55.2) <0.001
neobladder 38 (32.5) 9 (18.0) 29 (43.3)
However, patients in the ORC group had a slightly higher ASA score and patients
in the RARC group received significantly more neo-adjuvant chemotherapy.
RARC patients had a significant longer operation time, but they received significantly
cutaneostomy 16 (13.7) 15 (30) 1 (1.5)
Bloodloss [ml, median (range)] 250 (5 – 1200) 300 (50 – 1200) 250 (5 – 1000) 0.042
28 missing 28 missing
Transfusion [n (%)] 30 (25.6) 28 (56.0) 2 (3.0) <0.001
Operation time [min, median 
(range)]
390 (115 – 720) 355 (115 – 655) 420 (240 – 720) <0.001
LoS [days, median (range)] 13 (3 – 75) 18 (3 – 75) 11 (5 – 36) <0.001
more PLND, more neobladder reconstruction and had less blood loss and a much lower transfusion rate.
Total 
(n=117)
Open (n=50) RARC (n=67) p-value
Complications In the RARC group, 16.4% of patients encountered a high-grade complication
Clavien Dindo 0 – 30 
days [n (%)]
0 39 (33.3) 19 (38.0) 20 (29.9) 0.005
I – II 56 (47.9) 16 (32.0) 40 (59.7)
III – IV 19 (16.2) 12 (24.0) 7 (10.4)
V 3 (2.6) 3 (6.0) -
Clavien Dindo 30 – 90 
days [n (%)]
0 81 (73.0) 42 (84.0) 39 (63.9) <0.001
I – II 19 (17.1) 1 (2.0) 18 (29.5)
III – IV
(CD III-V) in the first 90 days versus 40.0% of patients in the ORC group
(p=0.001). More low-grade complications (CD I-II) were registered in the 
RARC group, which could be due to the nature of the study design 
(prospective versus retrospective). RARC patients had a significantly shorter11 (9.9) 7 (14.0) 4 (6.6)
V - - -
Clavien Dindo 0 – 90 
days [n (%)]
0 26 (23.4) 15 (30.0) 11 (18.0) 0.001
I – II 55 (49.5) 15 (30.0) 40 (65.6)
III – IV 27 (24.3) 17 (34.0) 10 (16.4)
V 3 (2.7) 3 (6.0) -
Readmissions < 90 days [n (%)] 14 (12.7) 9 (18.0) 5 (8.3) 0.130
length of stay (LoS) in the hospital (11 versus 18 days) and a comparable
readmission rate.
Conclusion
RARC with intracorporeal urinary diversion was safely introduced despite the learning curve and without compromise in oncological
correct surgery or possible neobladder reconstruction. RARC can provide significant advantages over ORC regarding bloodloss, 
transfusion rate, high-grade complications and hospital stay.
Accurate and standardized reporting of complications is necessary to guide patient counseling.
